Stocks Retreating on New Evolution: Tenet Healthcare (NYSE:THC), Radius Health (NASDAQ:RDUS)

Tenet Healthcare Corp. (NYSE:THC) runs in leading trade, it felling -4.32% to traded at $14.38. THC attains analyst recommendation of 2.70 on scale of 1-5 with week’s performance of -2.59%. Tenet Healthcare Corporation (THC) and Centene Corporation (CNC) have signed a new, three-year agreement providing Centene and Health Net members with in-network access to Tenet’s hospitals, outpatient centers and employed physicians in 18 states.

“We are pleased to continue our long-standing relationship with Centene and Health Net, and to offer sustained network coverage to members who rely on our providers for high-quality healthcare services,” said Clint Hailey, chief managed care officer for Tenet.

To find out the technical position of THC, it holds price to book ratio of 2.83 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach. It has forward price to earnings ratio of 7.52. THC is presenting price to cash flow of 2.32 and free cash flow concluded as 9.89.

EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at -521.90%, and looking further price to next year’s EPS is 65.75%. While take a short look on price to sales ratio, that was 0.08.

Radius Health, Inc. (NASDAQ:RDUS) kept active in under and overvalue discussion, RDUS holds price to book ratio of 5.07 that presents much better indicator to find market price of a share price over its book value of equity for investment valuation.

The co is presenting price to cash flow as 5.18, the low single digit may indicate stock is undervalued and vice versa. On other hand, keeping in mind stable cash flows but few growth prospects make traders to value lower.

The firm has price volatility of 10.64% for a week and 6.65% for a month. Narrow down four to firm performance, its weekly performance was -24.58% and monthly performance was -21.48%.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *